10.46243/jst.2021.v6.i2.pp58-63 registered
Review on Defensive Roles of Thymoquinone NanobiosensoringProspective in Opposition to Cancer
Resolves to https://www.jst.org.in/index.php/pub/article/view/301
Held by Longman Publishers (India) · prefix 10.46243 live · DOI address https://doi.org/10.46243/jst.2021.v6.i2.pp58-63
Registered 29 Sep 2026 via crossref · record version 2 · last change 29 Sep 2026, 11:59 PM · record sha256 0508cc7a8d14b064…
Resolve ⬇ Record (JSON) ⬇ Kernel Metadata Declaration (XML) Compare with Crossref Cite (APA · BibTeX · RIS · CSL)
Also as schema.org JSON-LD · Turtle · RDF/XML · DataCite XML · Crossref UNIXREF · Crossref UNIXSD — the formats of the DOI content-negotiation service, from this record (which carries what).
What the DOI identifies
JournalArticle — an article in a journal · Digital · Visual · en
Review on Defensive Roles of Thymoquinone NanobiosensoringProspective in Opposition to Cancer (PrincipalTitle · en)
Published 2021-02-03
Part of Journal of Science & Technology · ISSN 2456-5660 · volume 06 · issue 02 · pages 58–63
Agents
- Dr.A. Mohamed Sikkander (author) · ORCID 0000-0002-8458-7448
- Dr.Khadeeja Yasmeen (author)
- Longman Publishers (publisher)
Identifiers DOI 10.46243/jst.2021.v6.i2.pp58-63
Abstract · en
Thymoquinone (TQ), the most important bioactive constituent of Nigella sativa, has been originating to exhibit anticancer effects in plentiful preclinical studies. Due to its multi targeting character, TQ interferes in an extensive assortment of tumorigenic processes and counteracts carcinogenesis, malicious growth, incursion, exodus, and angiogenesis. Moreover, TQ can exclusively sensitize tumor cells on the way to predictable cancer treatments (e.g.,chemotherapy, immunotherapy, and radiotherapy) and at the same time lessen psychoanalysis connected lethal effects in regular cells. In this review, we summarized the adjuvant prospective of TQ as observed in an assortment ofin vitroandin vivoanimal models and discussed the pharmacological properties of TQ to diminish its additional role in potentiating the usefulness of usual remedial modalities specifically surgery, radiotherapy, chemotherapy, and immunotherapy. On the whole we suggest supplementary ample evaluation of TQ in preclinical and clinical levels to demarcate its obscure usefulness as a novel corresponding adjuvant remedy for cancer treatment.
System metadata — ISO 26324:2025, Annex B · DOI Handbook 10.1
Each element by the standard's name (Annex B: reference elements, then administrative) and the Handbook's (in grey), read off the record above.
| Element | Value | In the record |
|---|---|---|
| DOI Name DOI name | 10.46243/jst.2021.v6.i2.pp58-63 | doi |
| Referent Type referentType | Creation | referent |
| Referent Sub-Type referentSubType | JournalArticle — an article in a journal | type |
| Referent Name(s) referentName(s) | Review on Defensive Roles of Thymoquinone NanobiosensoringProspective in Opposition to Cancer (PrincipalTitle, en) | titles |
| Basic Metadata basicMetadata | author: Dr.A. Mohamed Sikkander author: Dr.Khadeeja Yasmeen publisher: Longman Publishers published: 2021-02-03 part of: Journal of Science & Technology · ISSN 2456-5660 · vol. 06 · no. 02 · pp. 58–63 language: en form: Digital · Visual · Language | agents, dates, container, language, structural_type, modes, characters |
| Referent Identifier(s) alternateIdentifier(s) | none besides the DOI | identifiers, relations (IsSameAs) |
| Registration Authority registrationAuthorityCode | Crossref — issued by Crossref (member 25296); held here as a copy | record.source_agency (our code, ra_doi_name, for names issued here once appointed) |
| Created Date issueDate | 2026-09-08 | record.registered (when the DOI name was first registered) |
| relatedIdentifiers | none needed — the descriptive metadata is in this record | container, relations (only where the descriptive metadata lives at another identifier) |
complete Every System Metadata element is here, with the basic metadata a journal article needs.
The System Metadata Declaration (JSON) · the Kernel Metadata Declaration (XML) · what each sub-type needs
Cited by — in this registry
No record held in this registry cites this DOI.
Counts only records held in this registry; a citation from a work held elsewhere is not seen here. The list as JSON
References with DOIs
The record lists 24 references; 21 carry a DOI.
| # | Reference | DOI | Held here |
|---|---|---|---|
| 2 | ref2 El-Far, A.H. Thymoquinone anticancer discovery: Possible mechanisms. Curr. Drug Discov. Technol. 2015, 12, 80–89. [CrossRef] [PubMed] | 10.2174/1570163812666150716111821 | not held here |
| 3 | ref3 El-Far, A.H.; Korshom, M.A.; Mandour, A.A.; El-Bessoumy, A.A.; El-Sayed, Y.S. Hepatoprotective efficacy of Nigella sativa seeds dietary supplementation against lead acetate-induce… | 10.1016/j.biopha.2017.02.044 | not held here |
| 4 | ref4 Banerjee, S.; Padhye, S.; Azmi, A.; Wang, Z.W.; Philip, P.A.; Kucuk, O.; Sarkar, F.H.; Mohammad, R.M. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr… | 10.1080/01635581.2010.509832 | not held here |
| 5 | ref5 Darakhshan, S.; Pour, A.B.; Colagar, A.H.; Sisakhtnezhad, S. Thymoquinone and its therapeutic potentials. Pharmacol. Res. 2015, 95–96, 138–158. [CrossRef] [PubMed] | 10.1016/j.phrs.2015.03.011 | not held here |
| 6 | ref6 Salmani, J.M.; Asghar, S.; Lv, H.X.; Zhou, J.P. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and l… | 10.3390/molecules19055925 | not held here |
| 7 | ref7 Alkharfy, K.M.; Ahmad, A.; Khan, R.M.; Al-Shagha, W.M. Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur. J. Drug Met… | 10.1007/s13318-014-0207-8 | not held here |
| 8 | ref8 Schneider-Stock, R.; Fakhoury, I.H.; Zaki, A.M.; El-Baba, C.O.; Gali-Muhtasib, H.U. Thymoquinone: Fifty years of success in the battle against cancer models. Drug Discov. Today 20… | 10.1016/j.drudis.2013.08.021 | not held here |
| 9 | ref9 Ballout, F.; Habli, Z.; Rahal, O.N.; Fatfat, M.; Gali-Muhtasib, H. Thymoquinone-based nanotechnology for cancer therapy: Promises and challenges. Drug Discov. Today 2018, 23, 1089… | 10.1016/j.drudis.2018.01.043 | not held here |
| 10 | ref10 Gupta, B.; Ghosh, K.K. Thymoquinone. In Nutraceuticals: Efficacy, Safety and Toxicity; Gupta, R.C., Ed.; Elsevier: Boston, MA, USA, 2016; pp. 541–550 | 10.1016/b978-0-12-802147-7.00039-5 | not held here |
| 11 | ref11 Imran, M.; Rauf, A.; Khan, I.A.; Shahbaz, M.; Qaisrani, T.B.; Fatmawati, S.; Abu-Izneid, T.; Imran, A.; Ur Rahman, K.; Gondal, T.A. Thymoquinone: A novel strategy to combat cancer… | 10.1016/j.biopha.2018.06.159 | not held here |
| 13 | ref13 Srinivas, P.R.; Philbert, M.; Vu, T.Q.; Huang, Q.; Kokini, J.L.; Saltos, E.; Chen, H.; Peterson, C.M.; Friedl, K.E.; McDade-Ngutter, C.; et al. Nanotechnology research: Applicatio… | 10.3945/jn.109.115048 | not held here |
| 14 | ref14 Li, W.; Yalcin, M.; Lin, Q.; Ardawi, M.M.; Mousa, S.A. Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery. J. Control. Release 2017, 248, … | 10.1016/j.jconrel.2017.01.009 | not held here |
| 15 | ref15 Weiss, J.; Takhistov, P.; McClements, D.J. Functional materials in food nanotechnology. J. Food Sci. 2006, 71, R107–R116. [CrossRef] 62 | Page | 10.1111/j.1750-3841.2006.00195.x | not held here |
| 16 | ref16 Nihei, T.; Suzuki, H.; Aoki, A.; Yuminoki, K.; Hashimoto, N.; Sato, H.; Seto, Y.; Onoue, S. Development of a novel nanoparticle formulation of thymoquinone with a cold wet-milling… | 10.1016/j.ijpharm.2016.07.038 | not held here |
| 17 | ref17 Zamboni, W.C. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008, 13, 248–260. [CrossRef] [PubMed] | 10.1634/theoncologist.2007-0180 | not held here |
| 18 | ref18 Gali-Muhtasib H, Ocker M, Kuester D, Krueger S, El-Hajj Z, et al. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J C… | 10.1111/j.1582-4934.2007.00095.x | not held here |
| 19 | ref19 Badary OA, Al-Shabanah OA, Nagi MN, Al-Rikabi AC, Elmazar MM. Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur J Cancer Prev. 1999;8:43… | 10.1097/00008469-199910000-00009 | not held here |
| 21 | ref21 Badary OA, Nagi MN, al-Shabanah OA, al-Sawaf HA, al-Sohaibani MO, et al. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor … | 10.1139/y97-169 | not held here |
| 22 | ref22 Badary OA. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol. 1999;67:135–142 | 10.1016/s0378-8741(98)00242-6 | not held here |
| 23 | ref23 Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwari S, et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007… | 10.1158/0008-5472.can-07-1483 | not held here |
| 24 | ref24 Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 2009;11:373–… | 10.1111/j.1477-2574.2009.00059.x | not held here |
Relations
The record states no relation, and no record held here states one with this DOI.
Funding
The record names no funder.
Each funder's page lists every work held here that names it. ROR IDs open at ror.org; Funder Registry IDs resolve at doi.org.
History — the ledger
Every change to this DOI, in order, as it was recorded. Entries are only ever added, never changed or removed.
| # | When | What | By | Changes |
|---|---|---|---|---|
| 1 | 29 Sep 2026, 10:00 PM | register registered at Crossref; record read from api.crossref.org | Administrator (admin) | 128 fields set · sha256 2a3ab169f6a3… |
| 2 | 29 Sep 2026, 11:59 PM | update record re-read from api.crossref.org | Administrator (admin) | container.titles.0.value: |
Machine-readable: the history as JSON, with the full record after each change.
Changes made at Crossref through DOI Doctor
Every deposit Smart Scholars' DOI Doctor made for this DOI, oldest first, with Crossref's own answer. Each fingerprint is the SHA-256 of its entry and of the fingerprint before it, so a change to any earlier entry changes every fingerprint after it.
| When | What changed | Crossref | Fingerprint |
|---|---|---|---|
| 11 Sep 2026, 05:18 | Address updated from https://www.jst.org.in/index.php/pub/article/view/301/264 to https://www.jst.org.in/index.php/pub/article/view/301 | ● accepted by Crossref | b85e1bbec973… |
| 13 Sep 2026, 01:40 | Read back: the DOI resolves to the new address | ● confirmed | 445c399c81ca… |
| 15 Oct 2026, 15:30 | Metadata completed abstract (152 words) · licence | ● accepted by Crossref | cc5cfcb7afe5… |
| 15 Oct 2026, 16:19 | Read back: Crossref's record shows it | ● confirmed | ba15c0ed4bbc… |
4 entries · the last fingerprint ba15c0ed4bbccca2780835b43d6eadfd571c3fe9f3eded711492e351fff32b4b · the history as JSON, each entry with the fingerprint before it, to check them yourself.



